Prospective RCT Lidocaine & Levobupivacaine on Block Dynamics After Subparaneural Popliteal Sciatic Nerve Block
Launched by CHINESE UNIVERSITY OF HONG KONG · May 20, 2020
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating the effects of two different local anesthetics, lidocaine and levobupivacaine, when injected near the sciatic nerve in the back of the knee, which is often done to help manage pain during foot or ankle surgeries. The researchers want to find out if using lidocaine helps patients feel ready for surgery faster compared to levobupivacaine. They believe that injecting lidocaine below a specific point of the nerve may speed up the process of getting the area numb.
To participate in this study, individuals should be adults aged between 18 and 80 who are scheduled for elective foot surgery and are in good health (ASA physical status I-III). However, people who are pregnant, have certain health conditions, or have had previous surgeries in that area may not be eligible. Participants will receive either lidocaine or levobupivacaine before their surgery, and the researchers will monitor how quickly the anesthesia takes effect and how effective it is. This trial aims to improve the way pain is managed for patients undergoing these types of surgeries.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • American Society of Anesthesiologists (ASA) physical status I-III
- • adult and scheduled to undergo elective forefoot surgery under regional anaesthesia
- Exclusion Criteria:
- • patient refusal
- • ASA physical status \> III
- • pregnancy
- • neuromuscular disorder
- • prior surgery in the popliteal fossa
- • coagulopathy
- • allergy to local anaesthetic drugs
- • skin infection at the site of needle insertion
About Chinese University Of Hong Kong
The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shatin, New Territories, Hong Kong
Patients applied
Trial Officials
Manoj K Karmakar, MD
Principal Investigator
Chinese University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials